Fecal Microbiota Transplantation to RESCUE Patients With Unresectable Hcc Progressors to First Line Therapy With AtezolizUmaB and Bevacizumab
NCT ID: NCT07276100
Last Updated: 2025-12-10
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
RECRUITING
Clinical Phase
PHASE2
Total Enrollment
15 participants
Study Classification
INTERVENTIONAL
Study Start Date
2026-01-01
Study Completion Date
2029-01-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The purpose of this study is to evaluate whether fecal microbiota transplantation (FMT), when administered in combination with atezolizumab and bevacizumab, can improve treatment response in participants with hepatocellular carcinoma (HCC) whose disease has progressed during prior atezolizumab-bevacizumab therapy. The study will also assess the safety and feasibility of this treatment strategy.
Primary Objective:
To determine whether FMT can restore or enhance response to atezolizumab and bevacizumab following disease progression.
Participants will:
Receive a fecal microbiota transplantation (FMT).
Resume treatment with atezolizumab and bevacizumab, administered every 3 weeks.
Primary Objective:
To determine whether FMT can restore or enhance response to atezolizumab and bevacizumab following disease progression.
Participants will:
Receive a fecal microbiota transplantation (FMT).
Resume treatment with atezolizumab and bevacizumab, administered every 3 weeks.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Atezolizumab-bevacizumab and Other Immunotherapies: Real-life Experience for Treatment of Hepatocellular Carcinoma
NCT06806579
Hepatocellular Carcinoma (HCC)
RECRUITING
A Study of Participants With Initially Unresectable Hepatocellular Carcinoma That is Treated With Atezolizumab and Bevacizumab Plus Transarterial Chemoembolization
NCT06503250
Unresectable Hepatocellular Carcinoma
COMPLETED
A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-Pugh B7 and B8 Cirrhosis
NCT06096779
Hepatocellular Carcinoma
RECRUITING
PHASE2
A Study of Atezolizumab (Tecentriq) in Combination With Bevacizumab to Investigate Safety and Efficacy in Patients With Unresectable Hepatocellular Carcinoma Not Previously Treated With Systemic Therapy-Amethista
NCT04487067
Carcinoma, Hepatocellular
COMPLETED
PHASE3
An Observational Study to Learn More About How Well a Treatment Works When Given After Treatment With Atezolizumab and Bevacizumab or Another Similar Combination of Drugs in Adults With Liver Cancer That Cannot be Treated With Surgery
NCT06117891
Unresectable Hepatocellular Carcinoma
RECRUITING
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Hepato Cellular Carcinoma (HCC)
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NA
Intervention Model
SINGLE_GROUP
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
experimental
Fecal microbiota transplantation (FMT) + atezolizumab (1200 mg flat dose) and bevacizumab (15 mg/kg) Q3W
Group Type
EXPERIMENTAL
Fecal microbiota transplantation (FMT)
Intervention Type
OTHER
Fecal microbiota transplantation (FMT)
Atezolizumab & Bevacizumab
Intervention Type
DRUG
Atezolizumab \& Bevacizumab
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Fecal microbiota transplantation (FMT)
Fecal microbiota transplantation (FMT)
Intervention Type
OTHER
Atezolizumab & Bevacizumab
Atezolizumab \& Bevacizumab
Intervention Type
DRUG
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Signed Informed Consent Form.
2. Age ≥ 18 years.
3. Tolerance to first-line treatment for HCC with atezolizumab plus bevacizumab, defined as absence of adverse events requiring permanent discontinuation of either drug.
4. Ability to comply with all study procedures, in the investigator's judgment.
5. Unresectable hepatocellular carcinoma with early disease progression on first-line atezolizumab + bevacizumab (within 4 months of treatment initiation).
6. At least one untreated measurable lesion per RECIST 1.1.
7. ECOG Performance Status 0-1.
8. Child-Pugh class A.
9. Adequate hematologic and end-organ function (laboratory values obtained within 7 days prior to enrollment), defined as follows:
1. ANC ≥ 1.5 × 10⁹/L (1500/µL), without G-CSF support.
2. Lymphocyte count ≥ 0.5 × 10⁹/L (500/µL).
3. Platelet count ≥ 60 × 10⁹/L (60,000/µL), without transfusion.
4. Hemoglobin ≥ 90 g/L (9 g/dL); transfusion allowed if last transfusion ≥ 3 weeks prior.
5. AST, ALT, and ALP ≤ 5 × ULN.
6. Total bilirubin ≤ 3 × ULN.
7. Serum creatinine ≤ 1.5 × ULN or creatinine clearance ≥ 50 mL/min (Cockcroft-Gault).
8. Serum albumin ≥ 28 g/L (2.8 g/dL), without infusion supplementation in previous 2 months.
9. INR and aPTT ≤ 1.5 × ULN.
10. Women of childbearing potential:
a. Agree to remain abstinent or use effective contraception (failure rate \<1%/year) during treatment and for 5 months after last atezolizumab dose and 6 months after last bevacizumab dose.
b. Agree to refrain from donating eggs during this period.
11. Men with female partners of childbearing potential:
1. Agree to remain abstinent or use a condom plus an additional contraceptive method (combined failure rate \<1%/year) during treatment and for 6 months after last bevacizumab dose.
2. Agree to refrain from donating sperm during this period.
2. Age ≥ 18 years.
3. Tolerance to first-line treatment for HCC with atezolizumab plus bevacizumab, defined as absence of adverse events requiring permanent discontinuation of either drug.
4. Ability to comply with all study procedures, in the investigator's judgment.
5. Unresectable hepatocellular carcinoma with early disease progression on first-line atezolizumab + bevacizumab (within 4 months of treatment initiation).
6. At least one untreated measurable lesion per RECIST 1.1.
7. ECOG Performance Status 0-1.
8. Child-Pugh class A.
9. Adequate hematologic and end-organ function (laboratory values obtained within 7 days prior to enrollment), defined as follows:
1. ANC ≥ 1.5 × 10⁹/L (1500/µL), without G-CSF support.
2. Lymphocyte count ≥ 0.5 × 10⁹/L (500/µL).
3. Platelet count ≥ 60 × 10⁹/L (60,000/µL), without transfusion.
4. Hemoglobin ≥ 90 g/L (9 g/dL); transfusion allowed if last transfusion ≥ 3 weeks prior.
5. AST, ALT, and ALP ≤ 5 × ULN.
6. Total bilirubin ≤ 3 × ULN.
7. Serum creatinine ≤ 1.5 × ULN or creatinine clearance ≥ 50 mL/min (Cockcroft-Gault).
8. Serum albumin ≥ 28 g/L (2.8 g/dL), without infusion supplementation in previous 2 months.
9. INR and aPTT ≤ 1.5 × ULN.
10. Women of childbearing potential:
a. Agree to remain abstinent or use effective contraception (failure rate \<1%/year) during treatment and for 5 months after last atezolizumab dose and 6 months after last bevacizumab dose.
b. Agree to refrain from donating eggs during this period.
11. Men with female partners of childbearing potential:
1. Agree to remain abstinent or use a condom plus an additional contraceptive method (combined failure rate \<1%/year) during treatment and for 6 months after last bevacizumab dose.
2. Agree to refrain from donating sperm during this period.
Exclusion Criteria
1\. History of leptomeningeal disease or brain metastases.
2\. Active or prior autoimmune disease or immune deficiency (e.g., myasthenia gravis, myositis, autoimmune hepatitis, SLE, RA, IBD, antiphospholipid syndrome, Wegener, Sjögren, Guillain-Barré, MS), except:
1. Autoimmune hypothyroidism on replacement therapy.
2. Controlled Type 1 diabetes on insulin.
3. Dermatologic-only autoimmune diseases (eczema, psoriasis, lichen simplex chronicus, vitiligo) if:
1\. Rash \<10% BSA. 2. Well-controlled on low-potency topical steroids. 3. No exacerbations requiring systemic therapy within 12 months.
3\. History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on CT (radiation pneumonitis in field allowed).
4\. Active tuberculosis.
5\. Significant cardiovascular disease within 3 months (NYHA ≥ II, MI, CVA), unstable arrhythmia, or unstable angina.
6\. Congenital long-QT syndrome or QTcF \>500 ms at screening.
7\. Active advanced malignancy other than HCC within 1 year.
8\. Prior severe adverse reaction to atezolizumab or bevacizumab unmanageable with low-dose steroids or requiring discontinuation.
9\. Uncorrectable electrolyte abnormalities (K, Ca, Mg).
10\. Major surgery within 4 weeks or planned major surgery during study.
11\. Severe infection within 4 weeks (including hospitalization, bacteremia, severe pneumonia).
12\. Therapeutic oral/IV antibiotics within 2 weeks (prophylactic antibiotics allowed). All within 30 days has to be recorded in eCRF.
13\. Prior allogeneic stem cell or solid organ transplantation.
14\. Any condition or laboratory abnormality posing excessive risk or interfering with study results.
15\. Live attenuated vaccine within 4 weeks before treatment or planned during or 5 months after atezolizumab.
16\. Severe allergic or anaphylactic reaction to humanized antibodies or fusion proteins.
17\. Hypersensitivity to CHO cell products or components of atezolizumab or bevacizumab.
18\. Pregnancy or breastfeeding; intent to become pregnant during treatment or post-treatment windows.
Pregnancy test required within 14 days pre-treatment.
19\. Fibrolamellar HCC, sarcomatoid HCC, or combined HCC-cholangiocarcinoma.
20\. Untreated or high-risk esophageal/gastric varices. EGD required; prophylactic treatment mandated.
21\. Variceal bleeding within 6 months.
22\. Clinically evident ascites.
23\. Episode of encephalopathy within 3 months.
24\. HBV/HCV co-infection.
25\. Patients with prior HCV but negative HCV RNA are considered non-infected.
26\. Prior systemic therapy for advanced HCC other than first-line atezolizumab + bevacizumab.
27\. Systemic immunostimulatory agents (e.g., interferon, IL-2) within 4 weeks or 5 half-lives.
28\. Symptomatic, untreated, or actively progressing CNS metastases. Eligible only if all criteria are met: extracranial measurable disease, no hemorrhage history, lesions limited to cerebellum/supratentorial region, no progression post-therapy, no recent RT/surgery, no steroid requirement, stable anticonvulsants, new lesions treated before enrollment.
29\. Uncontrolled tumor-related pain; symptomatic lesions requiring RT must be treated first.
30\. Uncontrolled pleural effusion, pericardial effusion, or ascites requiring ≥ monthly drainage.
Indwelling catheters allowed.
31\. Uncontrolled or symptomatic hypercalcemia.
32\. Investigational therapy (other than atezolizumab + bevacizumab) within 28 days.
33\. Systemic immunosuppressive therapy within 2 weeks, except:
1. Acute, low-dose, or one-time pulse steroids.
2. Mineralocorticoids, inhaled steroids, low-dose steroids for adrenal insufficiency/orthostatic hypotension.
34\. Uncontrolled hypertension (SBP \>150 mmHg and/or DBP \>100 mmHg on multiple readings).
35\. Prior hypertensive crisis or hypertensive encephalopathy.
36\. Significant vascular disease within 6 months.
37\. Hemoptysis \>2.5 mL within 1 month.
38\. Bleeding diathesis or significant coagulopathy.
39\. Current or recent (within 10 days of first dose of study treatment) use of aspirin \>325 mg/day or treatment with dipyramidole, ticlopidine, clopidogrel, and cilostazol.
40\. Current or recent (within 10 days prior to study treatment start) use of full dose oral or parenteral anticoagulants or thrombolytic agents for therapeutic (as opposed to prophylactic) purpose. Prophylactic anticoagulation for the patency of venous access devices is allowed provided the activity of the agent results in an INR \< 1.5 x ULN and aPTT is within normal limits (ratio \<1.5) within 14 days prior to initiation of study treatment.
41\. Core biopsy or minor surgery (except vascular access) within 3 days of first bevacizumab dose.
42\. History of abdominal or tracheoesophageal fistula, GI perforation, or intra-abdominal abscess within 6 months.
43\. History of intestinal obstruction and/or clinical signs or symptoms of GI obstruction including subocclusive disease related to the underlying disease or requirement for routine parenteral hydration, parenteral nutrition, or tube feeding prior to initiation of study treatment. Patients with signs/symptoms of sub-/occlusive syndrome/intestinal obstruction at time of initial diagnosis may be enrolled if they had received definitive (surgical) treatment for symptom resolution.
44\. Abdominal free air not explained by procedure or surgery.
45\. Serious non-healing wound, ulcer, or untreated bone fracture.
46\. Metastatic disease involving major airways/blood vessels or large mediastinal masses (\<30 mm from carina).
Portal/hepatic vein invasion allowed.
47\. Intra-abdominal inflammatory process (e.g., complicated PUD, diverticulitis, colitis) within 6 months.
48\. Radiotherapy within 28 days (or abdominal/pelvic RT within 60 days), except palliative bone RT within 7 days.
49\. Local liver therapy (RFA, ethanol, cryoablation, HIFU, TACE, TAE, SIRT) within 28 days or incomplete recovery.
50\. Major surgery, open biopsy, abdominal surgery, abdominal intervention, or significant trauma within the specified windows or unresolved from such events.
51\. Chronic daily NSAID use, except aspirin \<325 mg/day. Occasional use allowed.
2\. Active or prior autoimmune disease or immune deficiency (e.g., myasthenia gravis, myositis, autoimmune hepatitis, SLE, RA, IBD, antiphospholipid syndrome, Wegener, Sjögren, Guillain-Barré, MS), except:
1. Autoimmune hypothyroidism on replacement therapy.
2. Controlled Type 1 diabetes on insulin.
3. Dermatologic-only autoimmune diseases (eczema, psoriasis, lichen simplex chronicus, vitiligo) if:
1\. Rash \<10% BSA. 2. Well-controlled on low-potency topical steroids. 3. No exacerbations requiring systemic therapy within 12 months.
3\. History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on CT (radiation pneumonitis in field allowed).
4\. Active tuberculosis.
5\. Significant cardiovascular disease within 3 months (NYHA ≥ II, MI, CVA), unstable arrhythmia, or unstable angina.
6\. Congenital long-QT syndrome or QTcF \>500 ms at screening.
7\. Active advanced malignancy other than HCC within 1 year.
8\. Prior severe adverse reaction to atezolizumab or bevacizumab unmanageable with low-dose steroids or requiring discontinuation.
9\. Uncorrectable electrolyte abnormalities (K, Ca, Mg).
10\. Major surgery within 4 weeks or planned major surgery during study.
11\. Severe infection within 4 weeks (including hospitalization, bacteremia, severe pneumonia).
12\. Therapeutic oral/IV antibiotics within 2 weeks (prophylactic antibiotics allowed). All within 30 days has to be recorded in eCRF.
13\. Prior allogeneic stem cell or solid organ transplantation.
14\. Any condition or laboratory abnormality posing excessive risk or interfering with study results.
15\. Live attenuated vaccine within 4 weeks before treatment or planned during or 5 months after atezolizumab.
16\. Severe allergic or anaphylactic reaction to humanized antibodies or fusion proteins.
17\. Hypersensitivity to CHO cell products or components of atezolizumab or bevacizumab.
18\. Pregnancy or breastfeeding; intent to become pregnant during treatment or post-treatment windows.
Pregnancy test required within 14 days pre-treatment.
19\. Fibrolamellar HCC, sarcomatoid HCC, or combined HCC-cholangiocarcinoma.
20\. Untreated or high-risk esophageal/gastric varices. EGD required; prophylactic treatment mandated.
21\. Variceal bleeding within 6 months.
22\. Clinically evident ascites.
23\. Episode of encephalopathy within 3 months.
24\. HBV/HCV co-infection.
25\. Patients with prior HCV but negative HCV RNA are considered non-infected.
26\. Prior systemic therapy for advanced HCC other than first-line atezolizumab + bevacizumab.
27\. Systemic immunostimulatory agents (e.g., interferon, IL-2) within 4 weeks or 5 half-lives.
28\. Symptomatic, untreated, or actively progressing CNS metastases. Eligible only if all criteria are met: extracranial measurable disease, no hemorrhage history, lesions limited to cerebellum/supratentorial region, no progression post-therapy, no recent RT/surgery, no steroid requirement, stable anticonvulsants, new lesions treated before enrollment.
29\. Uncontrolled tumor-related pain; symptomatic lesions requiring RT must be treated first.
30\. Uncontrolled pleural effusion, pericardial effusion, or ascites requiring ≥ monthly drainage.
Indwelling catheters allowed.
31\. Uncontrolled or symptomatic hypercalcemia.
32\. Investigational therapy (other than atezolizumab + bevacizumab) within 28 days.
33\. Systemic immunosuppressive therapy within 2 weeks, except:
1. Acute, low-dose, or one-time pulse steroids.
2. Mineralocorticoids, inhaled steroids, low-dose steroids for adrenal insufficiency/orthostatic hypotension.
34\. Uncontrolled hypertension (SBP \>150 mmHg and/or DBP \>100 mmHg on multiple readings).
35\. Prior hypertensive crisis or hypertensive encephalopathy.
36\. Significant vascular disease within 6 months.
37\. Hemoptysis \>2.5 mL within 1 month.
38\. Bleeding diathesis or significant coagulopathy.
39\. Current or recent (within 10 days of first dose of study treatment) use of aspirin \>325 mg/day or treatment with dipyramidole, ticlopidine, clopidogrel, and cilostazol.
40\. Current or recent (within 10 days prior to study treatment start) use of full dose oral or parenteral anticoagulants or thrombolytic agents for therapeutic (as opposed to prophylactic) purpose. Prophylactic anticoagulation for the patency of venous access devices is allowed provided the activity of the agent results in an INR \< 1.5 x ULN and aPTT is within normal limits (ratio \<1.5) within 14 days prior to initiation of study treatment.
41\. Core biopsy or minor surgery (except vascular access) within 3 days of first bevacizumab dose.
42\. History of abdominal or tracheoesophageal fistula, GI perforation, or intra-abdominal abscess within 6 months.
43\. History of intestinal obstruction and/or clinical signs or symptoms of GI obstruction including subocclusive disease related to the underlying disease or requirement for routine parenteral hydration, parenteral nutrition, or tube feeding prior to initiation of study treatment. Patients with signs/symptoms of sub-/occlusive syndrome/intestinal obstruction at time of initial diagnosis may be enrolled if they had received definitive (surgical) treatment for symptom resolution.
44\. Abdominal free air not explained by procedure or surgery.
45\. Serious non-healing wound, ulcer, or untreated bone fracture.
46\. Metastatic disease involving major airways/blood vessels or large mediastinal masses (\<30 mm from carina).
Portal/hepatic vein invasion allowed.
47\. Intra-abdominal inflammatory process (e.g., complicated PUD, diverticulitis, colitis) within 6 months.
48\. Radiotherapy within 28 days (or abdominal/pelvic RT within 60 days), except palliative bone RT within 7 days.
49\. Local liver therapy (RFA, ethanol, cryoablation, HIFU, TACE, TAE, SIRT) within 28 days or incomplete recovery.
50\. Major surgery, open biopsy, abdominal surgery, abdominal intervention, or significant trauma within the specified windows or unresolved from such events.
51\. Chronic daily NSAID use, except aspirin \<325 mg/day. Occasional use allowed.
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
IRCCS Azienda Ospedaliero-Universitaria di Bologna
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Fabio Piscaglia
Head of Division of Internal Medicine, Hepatobiliary and Immunoallergic Diseases, IRCCS Azienda Ospedaliero-Universitaria di Bologna , Clinical Professor
Responsibility Role
PRINCIPAL_INVESTIGATOR
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
IRCCS AOU di Bologna Policlinico di Sant'Orsola
Bologna, BO, Italy
Site Status
RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
Italy
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2023-510504-45-00
Identifier Type: CTIS
Identifier Source: secondary_id
RESCUE-HUB
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Atezolizumab+Bevacizumab+SBRT in Unresectable HCC
NCT05096715
RECRUITING
PHASE1
Atezolizumab and Bevacizumab in Combination With TACE for Patients With BCLC B HCC
NCT05776875
TERMINATED
PHASE2
Neoadjuvant Atezo, Adjuvant Atezo + Beva Combined With RF Ablation of Small HCC: a Multicenter Randomized Phase II Trial
NCT04727307
RECRUITING
PHASE2
The Effectiveness and Safety in High-risk Patients Receiving First-line Atezolizumab and Bevacizumab Combined With HAIC for HCC: a Retrospective Study
NCT07272265
COMPLETED
NA
FMT in IT-refractory HCC - FAB-HCC Pilot Study
NCT05750030
COMPLETED
PHASE2
LOcoregional vs Systemic Therapy in Patients With BCLC Stage B HCC
NCT05537402
TERMINATED
PHASE2
Atezolizumab and Bevacizumab Pre-Liver Transplantation for Patients With Hepatocellular Carcinoma Beyond Milan Criteria
NCT05185505
RECRUITING
PHASE4
A Study to Evaluate of PM8002 Combined With PM1009 in Patients With First-line HCC
NCT06584071
NOT_YET_RECRUITING
PHASE1/PHASE2
A Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma
NCT03434379
COMPLETED
PHASE3
Transarterial Chemoembolization With Low-Dose Bevacizumab Plus Atezolizumab as First-Line Treatment for Unresectable Hepatocellular Carcinoma
NCT07281664
NOT_YET_RECRUITING
NA
Atezolizumab and Bevacizumab Before Surgery for the Treatment of Resectable Liver Cancer
NCT04721132
ACTIVE_NOT_RECRUITING
PHASE2
The Study of Atezolizumab, Bevacizumab and Memantine in Patients With Hepatocellular Carcinoma (HCC)
NCT06789757
RECRUITING
PHASE2
Advanced Therapies for Liver Metastases
NCT04622423
RECRUITING
A Study of ICP-192 in Patients With FGFR2-Rearranged Unresectable or Metastatic Intrahepatic Cholangiocarcinoma
NCT05678270
RECRUITING
PHASE2
Atezolizumab/Bevacizumab Followed by On-demand TACE or Initial Synchronous Treatment With TACE and Atezolizumab/Bevacizumab
NCT04224636
RECRUITING
PHASE2
A Study to Evaluate the Safety, Tolerability and Efficacy of RZ-001 in Combination With Valganciclovir (VGCV) and Atezolizumab/Bevacizumab in Subjects With Hepatocellular Carcinoma
NCT06695026
RECRUITING
PHASE1/PHASE2
Study of Atezolizumab and Bevacizumab With Y-90 TARE in Patients With Unresectable Hepatocellular Carcinoma (HCC)
NCT04541173
TERMINATED
PHASE2
A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular Carcionma
NCT04712643
ACTIVE_NOT_RECRUITING
PHASE3
Trial of PXS-5505 Combined With First Line Atezolizumab Plus Bevacizumab For Treating Patients With Unresectable Hepatocellular Carcinoma
NCT05109052
WITHDRAWN
PHASE1/PHASE2
Atezolizumab Plus Bevacizumab Combined With Locoregional Therapies in Unresectable Hepatocellular Carcinoma (ISMIO-001)
NCT07204327
ACTIVE_NOT_RECRUITING
Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer
NCT05168163
RECRUITING
PHASE2
Autologous Immune Cell Therapy in Primary Hepatocellular Carcinoma Patients Following Resection and TACE Therapy
NCT01828762
COMPLETED
NA
A Study of Valemetostat Tosylate (DS-3201b) With Atezolizumab and Bevacizumab in HCC
NCT06294548
RECRUITING
PHASE1/PHASE2